social linkedin box blue 32
social facebook box blue 32
social twitter box blue 32
social facebook box blue 32


News & Events ■ News ■ 2010 News

Alberto Diaspro launches Nanoscale Biophysics Subgroup at 2011 Biophysical Society

The IIT is pleased to announce that Alberto Diaspro launches the Nanoscale Biophysics Subgroup and Program at the 2011 Biophysical Society Meeting.

To learn more visit:

Last Updated on Wednesday, 08 December 2010 17:29

Synthesis, Structural Characterization and Modeling of the Growth of Colloidal Nanocrystals

Earlier this year Liberato Manna, Head of Nanochemistry gave a talk at the at the 2010 RBNI (Russel Berrie Nanotechnology Institute) winter school at Ein Gedi in Israel. The talk can be considered as a general introduction to the fabrication of nanostructures by colloidal chemical approaches.

Last Updated on Tuesday, 15 February 2011 14:00

Doctoral school Humanoid & Life Technologies XXVI Cycle

Please find below the admission tables in PDF format for the Doctoral Courses “Nanosciences”, "Robotics" and "Drug Discovery" Doctoral School on “Humanoid and Life Technologies” XXVI Cycle

Click here to see the original call

Admission Tables

Last Updated on Wednesday, 01 December 2010 12:16

Ground breaking study by D3 published in Nature Neuroscience

Potential first-in-class compound reveals new approach to the treatment of pain

 A new study has shown how a novel compound boosts levels of a natural painkiller at the site of an injury. The ground-breaking study published today in Nature Neuroscience shows how the potential drug URB937 acts in peripheral tissue and may have the potential to relieve pain without the side effects associated with many current painkillers that act centrally on the nervous system.

The preclinical study by the Drug Discovery and Development (D3) unit of the Istituto Italiano di Tecnologia and the University of California, showed that URB937, a potent, second-generation inhibitor of the enzyme fatty acid amide hydrolase (FAAH), controlled pain and inflammation locally at site by boosting levels of anandamide in peripheral tissues, part of the analgesic and anti-inflammatory endocannabinoid system. The compound is the first FAAH inhibitor produced with restricted access to the central nervous system (CNS), whereas current FAAH inhibitors readily cross the blood-brain barrier.1

Dr Daniele Piomelli, Scientific Director of D3, and lead investigator said: “These findings are significant because they show for the first time how FAAH inhibitors may enable the body to harness its own analgesic and anti-inflammatory powers right where the pain relief is needed and avoid side effects often seen in other painkillers. This has great potential to give patients more treatment options to relieve a wide spectrum of pain, such as rheumatoid arthritis and peripheral neuropathic pain.”

By circumventing the CNS, the compound may have numerous therapeutic advantages over current pain treatments such as opiates and non-steroidal anti-inflammatory drugs (NSAIDs) that can cause unwanted side effects in some patients such as nausea, bowel irritation and dependency.2, 3

Andrew Rice, Professor of Pain Research at Imperial College London, said: “This paper represents an important advance in the development of clinically useful cannabinoids. The existing laboratory and clinical data unequivocally demonstrate that cannabinoids have pain relieving properties, but their therapeutic index needs to be improved. By using a strategy of inhibiting an enzyme which inactivates endogenous cannabinoid only outside the brain and showing that this approach is still sufficient to retain an analgesic effect, Professor Piomelli and his colleagues have made a significant advance.”

D3 is continuing the development programme of URB937 and plans to begin clinical studies in 2012.

Investigators from other institutions were also involved in the study, including the universities of Urbino, Parma, Naples, and the Complutense University in Madrid.


About the D3

The D3 is a specialist unit of the Istituto Italiano di Tecnologia dedicated to the discovery of new medicines. The organisation focuses its research efforts on drug discovery in the three key therapeutic areas of pain, inflammation and dementia. By collaborating with private partners, the D3 brings together excellence in basic science from academia with the focus of the pharmaceutical industry to accelerate research in important areas of unmet medical need. Funded by the Italian government, the D3 will employ over 70 scientists and technical staff by December 2010. The organisation’s state-of-the-art facilities include 2000m2 of laboratory and office space completed in December 2009. For more information, visit


About the IIT

The Istituto Italiano di Tecnologia (IIT) is a foundation established jointly by the Italian Ministry of Education, Universities and Research and the Ministry of Economy and Finance to promote excellence in basic and applied research and to contribute to the economic development of Italy. The primary goals of the IIT are the creation and dissemination of scientific knowledge as well as the strengthening of Italy's technological competitiveness. To achieve these two goals, the IIT will cooperate with both academic institutions and private organisations, fostering through these partnerships scientific development, technological advances and training in high technology. For more information visit 


About the University of California, Irvine

Founded in 1965, UCI is a top-ranked university dedicated to research, scholarship and community service. Led by Chancellor Michael Drake since 2005, UCI is among the most dynamic campuses in the University of California system, with nearly 28,000 undergraduate and graduate students, 1,100 faculty and 9,000 staff. Orange County’s largest employer, UCI contributes an annual economic impact $3.9 billion. For more UCI news, visit


1.     Schlosburg, J.E., Kinsey, S.G. & Lichtman, A.H. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J. 11, 39-44 (2009)

2.     Hochman JS, Shah NR. What price pain relief? Circulation. 2006 Jun 27; 113(25):2868-70. Epub 2006 Jun 19. Erratum in: Circulation. 2006 Aug 22; 114(8):e364.

3.     Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003 Aug; 74(2):102-12.

Last Updated on Sunday, 28 November 2010 10:58

The 2010 “Premio Grande Ippocrate” awarded to pr Roberto Cingolani


At the ceremony held in Genova on Nov 15th, Pr Roberto Cingolani, Scientific Director of the Istituto Italiano di Tecnologia, received the award “Premio Grande Ippocrate” as acknowledgment of his communication skills.

Besides outstanding results in research, particularly in the application to medical science of principles issued from nanotechnology, pr Roberto Cingolani maintained a clear effort in the dissemination of scientific results to the broad audience, collaborating with journalists and media.

Established in 2008 by UNAMSI (Unione Nazionale Medico Scientifica d'Informazione, a free association established in 1951 to foster health education by means of seminars and papers) and Novartis (Novartis Farma S.p.A., the Italian branch of Novartis International AG), the “Premio Grande Ippocrate” has been awarded to Italian researchers in science medicine who stand jointly for their scientific activity and communication skills.

Download the press release (Italian only)

Last Updated on Monday, 22 November 2010 14:03


IIT's website uses the following types of cookies: browsing/session, analytics, functional and third party cookies. Users can choose whether or not to accept the use of cookies and access the website.
By clicking on further information, the full information notice on the types of cookies used will be displayed and you will be able to choose whether or not to accept cookies whilst browsing on the website.

Try our new site and tell us what you think
Take me there